Lion TCR Pte Ltd.

Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases.ROCKVILLE, Md. and SINGAPORE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, and Lion TCR, an Asia-based, clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-T cell therapies for solid tumors and life-threatening viral infections today announced the signing of a strategic platform license (SPL). This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets. Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual license fees and program-related revenue. “We are thrilled to partner with Lion TCR to support the development of their TCR-T cell therapies for hepatocellular carcinoma and life-threatening viral infections,” said Maher Masoud, President and CEO of MaxCyte. “Through this important partnership, we will be able to help provide the opportunity for patients in Asia (and ultimately patients worldwide) to benefit from these innovative mRNA-based TCR-T cell treatments and continue supporting the development of new therapies for patients with solid tumors.” Lion’s proprietary TCR-T cell therapy platform is supported by robust research, in collaboration with renowned laboratories, in the areas of autologous T cells and ’off-the-shelf’ technologies. The company’s TCR-T cell therapy harnesses the patient’s own immune system to fight against viral infections and cancers. The company is conducting ongoing clinical trials against hepatocellular carcinoma to evaluate the safety and efficacy of its TCR-T cells. Lion has engineered Hepatitis B virus (HBV)-specific T cells to recognize HBV-expressing tumor cells and achieve targeted killing, which is key as HBV is a major cause of hepatocellular carcinoma. “At Lion TCR, we aspire to be the world’s leader in the field of mRNA-based TCR-T therapeutics through the technological advancement and development of adoptive T cell therapy products for cancers and cancer-causing infectious diseases,” said CEO, Xiaoming Peng PhD, MBA. “We are honored to have MaxCyte as a partner and leverage their large-scale flow electroporation technology to support our development of novel therapeutics to benefit patients suffering from these devastating diseases.” MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Lion TCR is MaxCyte’s 24th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments. About MaxCyte At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn. About Lion TCR Pte LtdLion TCR, a clinical stage biotech spun off from Singapore’s A*STAR, specializes in engineered T Cell Receptor (TCR) T cell therapies for infectious diseases and associated cancers, particularly HBV-related hepatocellular carcinoma (HCC). Lion TCR have secured FDA IND approval for a Phase 1b/2 trial — the world’s first FDA-approved international multi-center trial for its HBV TCR-T therapy (LioCyx-M004) against HCC. Additionally, LioCyx-M004 has received dual Fast Track and Orphan Drug Designations from the FDA. Lion TCR's groundbreaking approach involves utilizing mRNA to encode HBV-specific TCR in patients' T cells, enabling the targeting of HBV epitopes expressed in liver cancer cells. Positive clinical trial outcomes attest to its efficacy. Building on their mRNA technology and AI-enabled TCR discovery platforms, Lion TCR extends its focus to solid tumors, offering personalized cell therapy and 'off-the-shelf' solutions. This positions Lion TCR to develop a robust pipeline for diverse solid cancers and chronic viral diseases. Learn more at liontcr.com. MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA +1 415-937-5400 ir@maxcyte.com US Media Relations Spectrum Seismic Collaborative Valerie Enes +1 408-497-8568 venes@spectrumscience.com Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden +44 (0)20 7886 2500 UK IR Adviser ICR ConsiliumMary-Jane Elliott Chris Welsh +44 (0)203 709 5700maxcyte@consilium-comms.com Lion TCR Contacts:2 Tukang Innovation Grove#09-04Singapore 618305 +65 68130738

SINGAPORE, September 14, 2022 - Lion TCR Pte Ltd, clinical-stage biotech company specialized in the development and commercialization of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers, has been recognized as the ‘Most Promising Cell & Gene Therapy Startup in Asia’ category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022, organized by IMAPAC. The award ceremony was held in conjunction with the 6th Cell & Gene Therapy World Asia 2022 conference on 14th – 15th of September at the Sheraton Tower in Singapore. Lion TCR managed to distinguish itself from other companies to win the recognition of the judges and industry leaders. Conference Presentation and Award Ceremony Dr Wai Lu-En, Director of Research & Development, shared the latest clinical developments of Lion TCR at the conference. Dr Sarene Koh, Director of Technology and Manufacturing, receiving "Most Promising Cell & Gene Therapy Startup in Asia' award. Lion TCR’s R&D Director Dr Wai Lu-En presented on ‘Advances in Liver Cancer Therapy Using our First-In-Class TCR-T Therapy’ as an invited speaker during the conference. Director of Technology and Manufacturing, Dr Sarene Koh, represented Lion TCR to receive the certificate and trophy for the ‘Most Promising Cell & Gene Therapy Startup in Asia’ award. Dr Wai Lu-En and Dr Sarene Koh are both A*STAR scholars, who obtained their PhDs from the prestigious Stanford University and Karolinska Institute respectively. They are the founding team members of the company, and joined Lion TCR’s scientific founder, Professor Antonio Bertoletti in the research and development of T-cell immunotherapy and the immuno-pathogenesis of hepatitis B virus infection. Dr Wai leads Lion TCR’s efforts to expand the TCR library and pipeline project, while Dr Koh leads Lion TCR's efforts on product development and process optimization in T cell immuno-therapy. Clinching the ‘Most Promising Cell & Gene Therapy Startup in Asia’ award represents the industry’s affirmation of the company’s achievements in immunotherapy. Lion TCR has obtained the world’s first Phase 1b/2 IND approval from the US FDA for its First-In-Class autologous TCR-T cell product (LioCyx-M004) for the treatment of HBV-related hepatocellular carcinoma (HCC). FDA has also granted Lion TCR the dual designations of Fast Track and Orphan Drug Designations (ODD) due to the novelty of LioCyx-M004 treatment and its efficacy in Phase I trials. Lion TCR’s endeavors to accelerate the pace of development and bring its products to patients faster. About Lion TCR Pte Ltd Lion TCR is a clinical-stage biotech company specialized in the development and commercialization of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers. As global leader in HBV-specific TCR redirected T cell therapy against HCC, the company is a biotech spin-off from Singapore’s Agency for Science, Technology and Research (A*STAR) and has global exclusive licenses of the technologies from A*STAR. Lion TCR has developed various TCR technology platforms including the TCR discovery as well as the autologous and allogeneic TCR that incorporate gene editing. About ACGTEA Asia-Pacific Cell & Gene Therapy Excellence Awards 2022 seeks to give recognition to exceptional cell & gene therapy pioneers, researchers, innovators and manufacturers that facilitate fast advancement in new therapies, R&D and manufacturing. Featuring top cell and gene therapy leaders in the industry, along with the new cell and gene therapy research development, latest advances and technologies and best practices in cell and gene manufacturing, the award applauds extraordinary leaders and trend-setters of today and inspires innovators of tomorrow. About IMAPAC IMAPAC is a prominent player in the biopharmaceutical community hosting networking sessions and conferences. It has organized many long running conferences such as the above Cell & Gene Therapy World Asia Conference as well as award ceremonies such as ACGTEA and the Asia-Pacific Bioprocessing Excellence Awards (ABEA) where notable winners include Cytiva and WuXi Biologics, where the latter was the winner for Bioprocessing Excellence in Viral Clearance and Safety in 2021 and 2022. ‍ ‍

NEW YORK, June 20, 2022 /PRNewswire/ -- According to the research report "Liver Cancer Drugs Market by Type and Geography - Forecast and Analysis 2022-2026", the market will witness a YOY growth of 10.4% at a CAGR of 14.67% during the forecast period. The report is segmented by type (immunotherapy and targeted therapy) and geography (North America, Europe, Asia, and Rest of World (ROW)). For more insights on YOY and CAGR, Read Sample Report Technavio has announced its latest market research report titled Liver Cancer Drugs Market by Type and Geography - Forecast and Analysis 2022-2026 Vendor Insights Global Liver Cancer Drugs Market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.  The report analyzes the market's competitive landscape and offers information on several market vendors, including: Alnylam Pharmaceuticals Inc. AstraZeneca Plc Bayer AG Bristol-Myers Squibb Co. Eisai Co. Ltd. Eli Lilly and Co. Eureka Therapeutics Exelixis Inc. F. Hoffmann La Roche Ltd. Gilead Sciences Inc. Jiangsu Hengrui Pharmaceuticals Co. Ltd. Lion TCR Pte. Ltd Merck and Co. Inc. Novartis AG Ono Pharmaceutical Co. Ltd. Pfizer Inc. Q BioMed Inc. Find additional highlights on the growth strategies adopted by vendors and their product offerings, Read Sample Report . Geographical Market Analysis North America will account for 42% of market growth. US and Canada are the key markets for liver cancer drugs in North America. Compared to the markets in Europe and Asia, this region's market will grow more slowly. Over the forecast period, the expansion of the liver cancer medications market in North America would be aided by the development and introduction of treatment regimens for the disease. Furthermore, countries such as the US, Canada, Germany, UK, and China are expected to emerge as prominent markets for Liver Cancer Drugs Market during the forecast period. Know more about this market's geographical distribution along with a detailed analysis of the top regions. Click Here for Sample Report. Competitive Analysis The competitive scenario provided in the liver cancer drugs market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Market Segmentation By Type, the market is classified as immunotherapy and targeted therapy. By Geography, the market is classified as North America, Europe, Asia, and the Rest of the World (ROW). To know about the market contribution of each segment – Get the latest sample report now! Key Market Drivers & Challenges: Factors such as the increasing incidence of liver cancer, and advancements in diagnostic methods will be crucial in driving the growth of the market. But factors such as the only curative option available is surgical resection and transplantation will restrict the market growth. The holistic analysis of the drivers & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge.Get a Sample for highlights on market Drivers & Challenges affecting Liver Cancer Drugs Market. Customize Your Report Don't miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. Do reach out to our analysts for more customized reports as per your requirements. Speak to an Analyst now! Related Reports: Rare Hemophilia Factors Market by Method and Geography - Forecast and Analysis 2022-2026 Obsessive-Compulsive Disorder Drugs Market by Product and Geography - Forecast and Analysis 2022-2026 Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Immunotherapy - Market size and forecast 2021-2026 Exhibit 28: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%) 5.4 Targeted therapy - Market size and forecast 2021-2026 Exhibit 32: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 China - Market size and forecast 2021-2026 Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%) 7.10 Canada - Market size and forecast 2021-2026 Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.11 UK - Market size and forecast 2021-2026 Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 AstraZeneca Plc Exhibit 85: AstraZeneca Plc - Overview Exhibit 86: AstraZeneca Plc - Product / Service Exhibit 87: AstraZeneca Plc - Key news Exhibit 88: AstraZeneca Plc - Key offerings 10.4 Bayer AG Exhibit 89: Bayer AG - Overview Exhibit 90: Bayer AG - Business segments Exhibit 91: Bayer AG - Key news Exhibit 92: Bayer AG - Key offerings Exhibit 93: Bayer AG - Segment focus 10.5 Bristol-Myers Squibb Co. Exhibit 94: Bristol-Myers Squibb Co. - Overview Exhibit 95: Bristol-Myers Squibb Co. - Product / Service Exhibit 96: Bristol-Myers Squibb Co. - Key offerings 10.6 Eisai Co. Ltd. Exhibit 97: Eisai Co. Ltd. - Overview Exhibit 98: Eisai Co. Ltd. - Business segments Exhibit 99: Eisai Co. Ltd. - Key offerings Exhibit 100: Eisai Co. Ltd. - Segment focus 10.7 Eli Lilly and Co. Exhibit 101: Eli Lilly and Co. - Overview Exhibit 102: Eli Lilly and Co. - Business segments Exhibit 103: Eli Lilly and Co. - Key offerings Exhibit 104: Eli Lilly and Co. - Segment focus 10.8 Eureka Therapeutics Exhibit 105: Eureka Therapeutics - Overview Exhibit 106: Eureka Therapeutics - Product / Service Exhibit 107: Eureka Therapeutics - Key offerings 10.9 Gilead Sciences Inc. Exhibit 108: Gilead Sciences Inc. - Overview Exhibit 109: Gilead Sciences Inc. - Business segments Exhibit 110: Gilead Sciences Inc. - Key news Exhibit 111: Gilead Sciences Inc. - Key offerings Exhibit 112: Gilead Sciences Inc. - Segment focus 10.10 Jiangsu Hengrui Pharmaceuticals Co. Ltd. Exhibit 113: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview Exhibit 114: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service Exhibit 115: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings 10.11 Lion TCR Pte. Ltd Exhibit 116: Lion TCR Pte. Ltd - Overview Exhibit 117: Lion TCR Pte. Ltd - Product / Service Exhibit 118: Lion TCR Pte. Ltd - Key offerings 10.12 Merck and Co. Inc. Exhibit 119: Merck and Co. Inc. - Overview Exhibit 120: Merck and Co. Inc. - Business segments Exhibit 121: Merck and Co. Inc. - Key news Exhibit 122: Merck and Co. Inc. - Key offerings Exhibit 123: Merck and Co. Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 124: Inclusions checklist Exhibit 125: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 126: Currency conversion rates for US$ 11.4 Research methodology Exhibit 127: Research methodology Exhibit 128: Validation techniques employed for market sizing Exhibit 129: Information sources 11.5 List of abbreviations Exhibit 130: List of abbreviations About Us: Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website:  SOURCE Technavio